{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:54:42Z","timestamp":1781542482346,"version":"3.54.5"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.blre.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T01:58:20Z","timestamp":1534730300000},"page":"106-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8084-9976","authenticated-orcid":false,"given":"Alessandro","family":"Di Minno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Spadarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Mormile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itala","family":"Ventre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Morfini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2018.08.003_bb0005","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.08.003_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pec.2010.04.039","article-title":"Non-adherence to medication and doctor-patient relationship: evidence from a European survey","volume":"83","author":"Stavropoulou","year":"2011","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.blre.2018.08.003_bb0015","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1377\/hlthaff.2011.1120","article-title":"The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment","volume":"31","author":"Grabowski","year":"2012","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.blre.2018.08.003_bb0020","first-page":"51","article-title":"Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism","volume":"4","author":"Kneeland","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.blre.2018.08.003_bb0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/11532870-000000000-00000","article-title":"Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help?","volume":"27","author":"Doggrell","year":"2010","journal-title":"Drugs Aging"},{"key":"10.1016\/j.blre.2018.08.003_bb0030","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11886-011-0221-2","article-title":"Predictors of statin adherence","volume":"13","author":"Mauskop","year":"2011","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.blre.2018.08.003_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2141.1958.tb03830.x","article-title":"Haemophilia and related conditions: a survey of 187 cases","volume":"4","author":"Biggs","year":"1958","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.08.003_bb0040","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1055\/s-0036-1579640","article-title":"Assessment of hemophilic arthropathy by ultrasound: where do we stand?","volume":"42","author":"Di Minno","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0045","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1046\/j.1365-2141.2000.02507.x","article-title":"Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease","volume":"111","author":"Lak","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.08.003_bb0050","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/1529-0131(199905)42:5<1025::AID-ANR23>3.0.CO;2-3","article-title":"Blood-induced joint damage: a human in vitro study","volume":"42","author":"Roosendaal","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2018.08.003_bb0055","first-page":"1350","article-title":"Cartilage damage as a result of hemarthrosis in a human in vitro model","volume":"24","author":"Roosendaal","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.blre.2018.08.003_bb0060","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2010-05-284653","article-title":"Neoangiogenesis contributes to the development of hemophilic synovitis","volume":"117","author":"Acharya","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.08.003_bb0065","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/ejh.12227","article-title":"Angiogenesis is increased in advanced haemophilic joint disease and characterised by normal pericyte coverage","volume":"92","author":"Zetterberg","year":"2014","journal-title":"Eur J Haematol"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2018.08.003_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2011.02615.x","article-title":"Joint protection in haemophilia","volume":"17","author":"Rodriguez-Merchan","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0075","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jpeds.2004.06.082","article-title":"Clinical and cost implications of target joints in Canadian boys with severe haemophilia A","volume":"145","author":"Kern","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.blre.2018.08.003_bb0080","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2516.1998.440413.x","article-title":"When should prophylactic treatment in patients with haemophilia A and B start?--The German experience","volume":"4","author":"Kreuz","year":"1998","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0085","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group","volume":"236","author":"Aledort","year":"1994","journal-title":"J Intern Med"},{"key":"10.1016\/j.blre.2018.08.003_bb0090","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2516.2005.01124.x","article-title":"Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed","volume":"11","author":"van Dijk","year":"2005","journal-title":"Haemophilia"},{"issue":"Suppl. 77","key":"10.1016\/j.blre.2018.08.003_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/ort.1965.36.suppl-77.01","article-title":"Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B","author":"Ahlberg","year":"1965","journal-title":"Acta Orthop Scand Suppl"},{"key":"10.1016\/j.blre.2018.08.003_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"10.1016\/j.blre.2018.08.003_bb0105","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/hae.12613","article-title":"How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access","volume":"21","author":"Nijdam","year":"2015","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2018.08.003_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2008.01946.x","article-title":"Haemophilia care then, now and in the future","volume":"15","author":"Oldenburg","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.08.003_bb0120","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with haemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1160\/TH14-05-0407","article-title":"Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study","volume":"114","author":"Tagliaferri","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13023-017-0660-y","article-title":"The cost of severe haemophilia in Europe: the CHESS study","volume":"12","author":"O'Hara","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2018.08.003_bb0135","first-page":"1","article-title":"Treatment of haemophilia: building on strength in the third millennium","volume":"17","author":"Mannucci","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0140","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/hae.12360","article-title":"Better adherence to prescribed treatment regimen is related to less chronic pain among adolescents and young adults with moderate or severe haemophilia","volume":"20","author":"McLaughlin","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0145","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH15-08-0637","article-title":"Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates","volume":"115","author":"Nijdam","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0150","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/hae.12904","article-title":"Promoting self-management and adherence during prophylaxis: evidence-based recommendations for haemophilia professionals","volume":"22","author":"Schrijvers","year":"2016","journal-title":"Haemophilia"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2018.08.003_bb0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2516.2012.02893.x","article-title":"From boy to man: recommendations for the transition process in haemophilia","volume":"18","author":"Young","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0160","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2516.2007.01625.x","article-title":"European principles of haemophilia care","volume":"14","author":"Colvin","year":"2008","journal-title":"Haemophilia"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2018.08.003_bb0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2516.2006.01256.x","article-title":"The natural evolution of haemophilia care: developing and sustaining comprehensive care globally","volume":"12","author":"Evatt","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0170","first-page":"CD003429","article-title":"Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with haemophilia A or B","author":"Iorio","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2018.08.003_bb0175","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/hex.12083","article-title":"Self-management and skills acquisition in boys with haemophilia","volume":"18","author":"Khair","year":"2015","journal-title":"Health Expect"},{"key":"10.1016\/j.blre.2018.08.003_bb0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2516.2006.01189.x","article-title":"Practice patterns in haemophilia A therapy \u2014 global progress towards optimal care","volume":"12","author":"Geraghty","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0185","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1365-2516.2009.02077.x","article-title":"Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2516.2007.01591.x","article-title":"Physicians' perceptions of adherence to prophylactic clotting factor infusions","volume":"14","author":"Thornburg","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.blre.2015.07.004","article-title":"Current concepts in the prevention of pathogen transmission via blood\/plasma-derived products for bleeding disorders","volume":"30","author":"Di Minno","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2018.08.003_bb0200","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0268-960X(03)00043-2","article-title":"Central venous catheters in children with haemophilia","volume":"18","author":"Ljung","year":"2004","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2018.08.003_bb0205","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1046\/j.1365-2516.2001.00534.x","article-title":"Barriers to compliance with prophylaxis therapy in haemophilia","volume":"7","author":"Hacker","year":"2001","journal-title":"Haemophilia"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2018.08.003_bb0210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2516.2007.01501.x","article-title":"Identifying and overcoming barriers to prophylaxis in the management of haemophilia","volume":"13","author":"Petrini","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0215","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2516.2008.01843.x","article-title":"A survey of adherence to haemophilia therapy in six European countries: results and recommendations","volume":"14","author":"De Moerloose","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0220","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1111\/j.1365-2516.2011.02578.x","article-title":"Predictors of treatment difficulties and satisfaction with haemophilia therapy in adult patients","volume":"17","author":"Remor","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0225","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2147\/PPA.S64709","article-title":"Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries","volume":"8","author":"Cimino","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.blre.2018.08.003_bb0230","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/hae.12079","article-title":"Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review","volume":"19","author":"Schrijvers","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169880","article-title":"Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a quantitative study with patients","volume":"12","author":"van Os","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2018.08.003_bb0240","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2516.2009.02129.x","article-title":"VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia","volume":"16","author":"Duncan","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0245","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2516.2012.02813.x","article-title":"Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States","volume":"18","author":"Duncan","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0250","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/hae.12432","article-title":"Development and psychometric evaluation of a novel tool for assessing patient perception and preference for haemophilia treatment (HaemoPREF)","volume":"20","author":"Teal","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0255","series-title":"ISPOR 19th Annual European Congress October 29th-November 2nd 2016, Vienna (Poster Presentation)","article-title":"Further validation of the HaemoPREF in a real-world setting","author":"Tolley","year":"2016"},{"key":"10.1016\/j.blre.2018.08.003_bb0260","first-page":"1687","article-title":"Patient and parent preferences for characteristics of prophylactic treatment in haemophilia","volume":"9","author":"Furlan","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.blre.2018.08.003_bb0265","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2516.2008.01926.x","article-title":"Patients', physicians', and pharmacists' preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study","volume":"15","author":"Scalone","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0270","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/j.1365-2516.2012.02771.x","article-title":"Why should we care about quality of life in persons with haemophilia?","volume":"18","author":"Aledort","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0275","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.blre.2018.08.003_bb0280","first-page":"1022","article-title":"Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis","volume":"17","author":"Ferraz","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.blre.2018.08.003_bb0285","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2516.2002.00581.x","article-title":"Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients","volume":"8","author":"Royal","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0290","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2516.2012.02765.x","article-title":"Quality of life in adult patients with haemophilia--a single centre experience from Sweden","volume":"18","author":"Lindvall","year":"2012","journal-title":"Haemophilia"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2018.08.003_bb0295","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2516.2008.01750.x","article-title":"Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG)","volume":"14","author":"Feldman","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0300","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2516.2006.01312.x","article-title":"Haemophilia joint health score reliability study","volume":"12","author":"Hilliard","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0305","unstructured":"HJHS. International Prophylaxis Study Group."},{"key":"10.1016\/j.blre.2018.08.003_bb0310","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/acr.20353","article-title":"Validation of a new pediatric joint scoring system from the International Haemophilia Prophylaxis Study Group: validity of the haemophilia joint health score","volume":"63","author":"Feldman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.blre.2018.08.003_bb0315","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/hae.12330","article-title":"Chinese Haemophilia Joint Health Score 2.1 reliability study","volume":"20","author":"Sun","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0320","doi-asserted-by":"crossref","DOI":"10.1111\/hae.12586","article-title":"Limits of agreement between raters are required for the use of HJHS 2.1 in clinical studies","volume":"21","author":"Fischer","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0325","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1111\/hae.12587","article-title":"Response to \u2018Limits of agreement between raters are required for use of HJHS 2.1 in clinical studies\u2019","volume":"21","author":"Feldman","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0330","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2040620717690316","article-title":"Point-of-care ultrasonography (POCUS) in haemophilia A: a commentary on current status and its potential role for improving prophylaxis management in severe haemophilia A","volume":"8","author":"Acharya","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2018.08.003_bb0335","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/hae.13249","article-title":"Imaging of haemophilic arthropathy in growing joints: pitfalls in ultrasound and MRI","volume":"23","author":"Soliman","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0340","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2516.2011.02682.x","article-title":"Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis","volume":"18","author":"Olivieri","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0345","series-title":"Albisetti M, et al","author":"von Mackensen","year":"2017"},{"key":"10.1016\/j.blre.2018.08.003_bb0350","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of haemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0355","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/hae.12916","article-title":"Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study","volume":"22","author":"Morfini","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0360","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13013","article-title":"The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO","volume":"22","author":"Collins","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0365","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/ejh.12359","article-title":"Innovative approach for improved rFVIII concentrate","volume":"93","author":"Morfini","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2018.08.003_bb0370","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/hae.12878","article-title":"Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B","volume":"22","author":"Kavakli","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0375","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/jth.12076","article-title":"Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein","volume":"11","author":"Peters","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0380","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe haemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.08.003_bb0385","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/hae.12887","article-title":"Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc","volume":"22","author":"Berntorp","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0390","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/hae.12671","article-title":"Switching from current factor VIII (FVIII) to longer acting FVIII concentrates\u2014what is the real potential benefit?","volume":"21","author":"Carcao","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0395","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2516.2004.01036.x","article-title":"A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia","volume":"10","author":"Ahnstrom","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0400","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0405","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1538-7836.2009.03703.x","article-title":"Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens","volume":"8","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0410","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0415","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0033-1354422","article-title":"Arthropathy in patients with moderate haemophilia a: a systematic review of the literature","volume":"39","author":"Di Minno","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0420","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ejh.12370","article-title":"Methods for individualising factor VIII dosing in prophylaxis","volume":"76","author":"Ar","year":"2014","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.blre.2018.08.003_bb0425","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/jth.12723","article-title":"Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels","volume":"12","author":"Shapiro","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"06","key":"10.1016\/j.blre.2018.08.003_bb0430","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1160\/TH16-12-0942","article-title":"Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates","volume":"117","author":"Iorio","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0435","doi-asserted-by":"crossref","DOI":"10.1111\/hae.13141","article-title":"Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT((R)) in patients with severe haemophilia A without inhibitors","volume":"23","author":"Alvarez-Roman","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0440","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.thromres.2017.07.003","article-title":"PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe haemophilia A","volume":"157","author":"Pasca","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2018.08.003_bb0445","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000488152","article-title":"The potential close future of haemophilia treatment - gene therapy, TFPI inhibition, antithrombin silencing, and mimicking factor VIII with an engineered antibody","volume":"45","author":"Korte","year":"2018","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.blre.2018.08.003_bb0450","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe haemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.08.003_bb0455","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Haemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.08.003_bb0460","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a haemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2018.08.003_bb0465","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.08.003_bb0470","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","article-title":"Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired haemophilia A","volume":"124","author":"Muto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.08.003_bb0475","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Haemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.08.003_bb0480","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with haemophilia A with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2018.08.003_bb0485","series-title":"Blood","first-page":"86","article-title":"Emicizumab Subcutaneous Dosing every 4 weeks for the management of haemophilia a: preliminary data from the pharmacokinetic run-in cohort of a multicenter, open-label, phase 3 study (HAVEN 4)","author":"Jimenez-Yuste","year":"2017"},{"key":"10.1016\/j.blre.2018.08.003_bb0490","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40265-018-0861-2","article-title":"Emicizumab-kxwh: First Global Approval","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2018.08.003_bb0495","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab Prophylaxis in Haemophilia A with Inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2018.08.003_bb0500","first-page":"154","article-title":"Tissue factor pathway inhibitor (TFPI)\u2014an update","volume":"26","author":"Sandset","year":"1996","journal-title":"Haemostasis"},{"key":"10.1016\/j.blre.2018.08.003_bb0505","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1073\/pnas.1119858109","article-title":"Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with haemophilia","volume":"109","author":"Maroney","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2018.08.003_bb0510","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00001721-199507000-00004","article-title":"Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A","volume":"6","author":"Erhardtsen","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2018.08.003_bb0515","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood-2007-07-098913","article-title":"Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with haemophilia A","volume":"111","author":"Prasad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.08.003_bb0520","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/jth.12201","article-title":"Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein","volume":"11","author":"Waters","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0525","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.thromres.2012.08.299","article-title":"Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of haemophilia","volume":"130","author":"Gissel","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2018.08.003_bb0530","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1538-7836.2012.04790.x","article-title":"Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma","volume":"10","author":"Gorczyca","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0535","first-page":"S168","article-title":"Thrombosis","volume":"515","author":"Willyard","year":"2014","journal-title":"Balancing Act Nat"},{"key":"10.1016\/j.blre.2018.08.003_bb0540","first-page":"297","article-title":"Effect of monoclonal antibody against human tissue factor pathway inhibitor on plasma coagulation time","volume":"22","author":"Yang","year":"1997","journal-title":"Hunan Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.blre.2018.08.003_bb0545","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"Waters","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0550","series-title":"Plasma tissue factor pathway inhibitor (TFPI) levels in healthy subjects and patients with haemophilia A and B","author":"Gu","year":"2016"},{"key":"10.1016\/j.blre.2018.08.003_bb0555","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1208\/s12248-017-0086-4","article-title":"Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys","volume":"19","author":"Gu","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.blre.2018.08.003_bb0560","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit haemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.08.003_bb0565","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejps.2014.02.009","article-title":"Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration","volume":"56","author":"Agerso","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.blre.2018.08.003_bb0570","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with haemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0575","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in haemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2018.08.003_bb0580","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of Antithrombin in Haemophilia A or B with RNAi Therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.08.003_bb0585","series-title":"Alnylam suspends fitusiran dosing due to thrombotic event in phase 2 open-label extension study","author":"Haemophilia WFo","year":"2017"},{"key":"10.1016\/j.blre.2018.08.003_bb0590","series-title":"FDA lifts suspension of fitusiran trial","author":"Haemophilia tWFo","year":"2017"},{"key":"10.1016\/j.blre.2018.08.003_bb0595","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1160\/TH11-07-0464","article-title":"Post-discharge compliance to venous thromboembolism prophylaxis in high-risk orthopaedic surgery: results from the ETHOS registry","volume":"107","author":"Bergqvist","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0600","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/MLR.0b013e31819a5acc","article-title":"Physician communication and patient adherence to treatment: a meta-analysis","volume":"47","author":"Zolnierek","year":"2009","journal-title":"Med Care"},{"key":"10.1016\/j.blre.2018.08.003_bb0605","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1741826711418166","article-title":"Compliance with cardiovascular drug prevention measures in a general population: the Multidisciplinary Intervention in Primary Care (IMAP) study","volume":"19","author":"Lopez-Carmona","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.blre.2018.08.003_bb0610","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.thromres.2014.01.016","article-title":"Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs)","volume":"133","author":"Di Minno","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2018.08.003_bb0615","first-page":"CD006594","article-title":"Reminder systems and late patient tracers in the diagnosis and management of tuberculosis","author":"Liu","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2018.08.003_bb0620","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1111\/hae.12107","article-title":"Magnetic resonance imaging and ultrasound evaluation of \u201chealthy\u201d joints in young subjects with severe haemophilia A","volume":"19","author":"Di Minno","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0625","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1160\/TH12-11-0874","article-title":"Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)","volume":"109","author":"Martinoli","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0630","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2147\/PPA.S99702","article-title":"The impact of using musculoskeletal ultrasound imaging and other influencing factors on medication adherence in patients with rheumatoid arthritis: a qualitative study","volume":"10","author":"Kumar","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.blre.2018.08.003_bb0635","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/1756-185X.12402","article-title":"Pilot study assessing the novel use of musculoskeletal ultrasound in patients with rheumatoid arthritis to improve patient attitudes and adherence to medication","volume":"19","author":"Joplin","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.blre.2018.08.003_bb0640","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1007\/s00296-011-2098-1","article-title":"Assessment of the utility of visual feedback in the treatment of early rheumatoid arthritis patients: a pilot study","volume":"32","author":"El Miedany","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.blre.2018.08.003_bb0645","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00296-016-3566-4","article-title":"Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe?","volume":"36","author":"Wong","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.blre.2018.08.003_bb0650","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197001","article-title":"Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: A pilot study","volume":"13","author":"Andersen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2018.08.003_bb0655","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.13034","article-title":"Perceptions of Doppler ultrasound for rheumatoid arthritis disease activity assessment and education","author":"Joshua","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.blre.2018.08.003_bb0660","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-017-1234-z","article-title":"Development of three-dimensional prints of arthritic joints for supporting patients' awareness to structural damage","volume":"19","author":"Kleyer","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.blre.2018.08.003_bb0665","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hae.13353","article-title":"Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein","volume":"24","author":"Oldenburg","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0670","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Tailored prophylaxis in severe haemophilia A: interim results from the first 5 years of the Canadian Haemophilia Primary Prophylaxis Study","volume":"4","author":"Feldman","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2018.08.003_bb0675","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1046\/j.1365-2516.2002.00694.x","article-title":"Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen","volume":"8","author":"Fischer","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2018.08.003_bb0680","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1365-2141.2001.02580.x","article-title":"Long-term outcome of individualized prophylactic treatment of children with severe haemophilia","volume":"112","author":"van den Berg","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.08.003_bb0685","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3324\/haematol.2016.156000","article-title":"Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine","volume":"102","author":"Di Minno","year":"2017","journal-title":"Haematologica"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X17300978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X17300978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T06:52:09Z","timestamp":1720507929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X17300978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":137,"alternative-id":["S0268960X17300978"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2018.08.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735981085.793562057","asserted-by":"object"}]},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}